[1]
|
于淼, 孙峥嵘. 人乳头瘤病毒致癌关键因素的研究进展[J]. 现代肿瘤医学, 2020, 28(5): 851-854.
|
[2]
|
Graham Sheila, V. (2017) The Human Papillomavirus Replication Cycle, and Its Links to Cancer Progression: A Comprehensive Review. Clinical Science, 131, 2201-2221. https://doi.org/10.1042/CS20160786
|
[3]
|
Gargan, S. and Stevenson, N.J. (2021) Unravelling the Immunomodulatory Effects of Viral Ion Channels, towards the Treatment of Disease. Virus-es, 13, Article 2165. https://doi.org/10.3390/v13112165
|
[4]
|
Bravo, I.G. and Alonso, A. (2004) Mucosal Human Papillomaviruses Encode Four Different E5 Proteins Whose Chemistry and Phylogeny Correlate with Malignant or Be-nign Growth. Journal of Virology, 78, 13613-13626.
https://doi.org/10.1128/JVI.78.24.13613-13626.2004
|
[5]
|
Fehrmann, F., Klumpp, D.J. and Laimins, L.A. (2003) Human Papillomavirus Type 31 E5 Protein Supports Cell Cycle Progression and Activates Late Viral Functions upon Epithelial Differentiation. Journal of Virology, 77, 2819-2831.
https://doi.org/10.1128/JVI.77.5.2819-2831.2003
|
[6]
|
付广红, 龚丹, 万佳. 人乳头瘤病毒16 E5(HPV16 E5)蛋白抑制角质形成细胞生长因子诱导的细胞自噬[J]. 细胞与分子免疫学杂志, 2016, 32(11): 1517-1521.
|
[7]
|
Ilahi, N.E. and Bhatti, A. (2019) Impact of HPV E5 on Viral Life Cycle via EGFR Signaling. Microbial Pathogenesis, 139, Article ID: 103923. https://doi.org/10.1016/j.micpath.2019.103923
|
[8]
|
Jawanjal, P., Salhan, S., Dhawan, I., et al. (2016) Augmented Activity of Cyclooxygenase-2 in Tissue and Serum of Patients with Cervical Cancer. Journal of Clin-ical Laboratory Analysis, 30, 1198-1207.
https://doi.org/10.1002/jcla.22003
|
[9]
|
Suprynowicz, F.A., Krawczyk, E., Hebert, J.D., et al. (2010) The Human Papillomavirus Type 16 E5 Oncoprotein Inhibits Epidermal Growth Factor Trafficking Independently of Endosome Acidification. Journal of Virology, 84, 10619-10629. https://doi.org/10.1128/JVI.00831-10
|
[10]
|
Zhang, B., Srirangam, A., Potter, D.A. and Roman, A. (2005) HPV16 E5 Protein Disrupts the c-Cbl-EGFR Interaction and EGFR Ubiquitination in Human Foreskin Keratinocytes. Oncogene, 24, 2585-2588.
https://doi.org/10.1038/sj.onc.1208453
|
[11]
|
Scott, M.L., Coleman, D.T., Kelly, K.C., et al. (2018) Human Papillo-mavirus Type 16 E5-Mediated Upregulation of Met in Human Keratinocytes. Virology, 519, 1-11. https://doi.org/10.1016/j.virol.2018.03.021
|
[12]
|
Bagarazzi, M.L., Yan, J., et al. (2012) Immunotherapy against HPV16/18 Generates Potent TH1 and Cytotoxic Cellular Immune Responses. Science Translational Medicine, 4, 155ra138. https://doi.org/10.1126/scitranslmed.3004414
|
[13]
|
Paolini, F., Curzio, G., Cordeiro, M.N., et al. (2017) HPV 16 E5 Oncoprotein Is Expressed in Early Stage Carcinogenesis and Can Be a Target of Immunotherapy. Human Vaccines & Immunotherapeutics, 13, 291-297.
https://doi.org/10.1080/21645515.2017.1264777
|
[14]
|
Maufort, J.P., Shai, A., Pitot, H.C. and Lambert, P.F. (2010) A Role for HPV16 E5 in Cervical Carcinogenesis. Cancer Research, 70, 2924-2931. https://doi.org/10.1158/0008-5472.CAN-09-3436
|
[15]
|
Hu, L. and Ceresa, B.P. (2009) Characterization of the Plasma Membrane Localization and Orientation of HPV16 E5 for Cell-Cell Fusion. Virology, 393, 135-143. https://doi.org/10.1016/j.virol.2009.07.034
|
[16]
|
唐志坚, 赵超, 李明珠, 等. 高危型人乳头瘤病毒感染的不同级别子宫颈病变患者细胞免疫状态分析[J]. 中国实用妇科与产科杂志, 2023, 39(10): 1024-1029.
|
[17]
|
Suprynowicz, F.A., Disbrow, G.L., Krawczyk, E., et al. (2008) HPV-16 E5 Oncoprotein Upregulates Lipid Raft Components Caveolin-1 and Ganglioside GM1 at the Plasma Membrane of Cervical Cells. Oncogene, 27, 1071-1078.
https://doi.org/10.1038/sj.onc.1210725
|
[18]
|
Speak, A.O., Cerundolo, V. and Platt, F.M. (2008) CD1d Presentation of Glycolipids. Immunology and Cell Biology, 86, 588-597. https://doi.org/10.1038/icb.2008.42
|
[19]
|
Miura, S., Kawana, K., Schust, D.J., et al. (2010) CD1d, a Sentinel Molecule Bridging Innate and Adaptive Immunity, Is Downreg-ulated by the Human Papillomavirus (HPV) E5 Protein: A Possible Mechanism for Immune Evasion by HPV. Journal of Virology, 84, 11614-11623. https://doi.org/10.1128/JVI.01053-10
|
[20]
|
Ashrafi, G.H., Haghshenas, M., Marchetti, B. and Campo, M.S. (2006) E5 Protein of Human Papillomavirus 16 Downregulates HLA Class I and Interacts with the Heavy Chain via Its First Hydrophobic Domain. International Journal of Cancer, 119, 2105-2112. https://doi.org/10.1002/ijc.22089
|
[21]
|
Ashrafi, G.H., Haghshenas, M.R., Marchetti, B., et al. (2005) E5 Protein of Human Papillomavirus Type 16 Selectively Downregulates Surface HLA Class I. International Journal of Cancer, 113, 276-283. https://doi.org/10.1002/ijc.20558
|
[22]
|
Scott, M.L., Woodby, B.L., Ulicny, J., et al. (2020) Human Papil-lomavirus 16 E5 Inhibits Interferon Signaling and Supports Episomal Viral Maintenance. Journal of Virology, 94, e01582-19. https://doi.org/10.1128/JVI.01582-19
|
[23]
|
Raikhy, G., Woodby, B.L., Scott, M.L., et al. (2019) Sup-pression of Stromal Interferon Signaling by Human Papillomavirus 16. Journal of Virology, 93, e00458-19. https://doi.org/10.1128/JVI.00458-19
|
[24]
|
张展, 刘朝晖. STING信号通路在HPV相关恶性肿瘤中的作用[J]. 国际妇产科学杂志, 2023, 50(1): 30-34.
|
[25]
|
Miyauchi, S., Kim, S.S., Jones, R.N., et al. (2023) Human Papilloma-virus E5 Suppresses Immunity via Inhibition of the Immunoproteasome and STING Pathway. Cell Reports, 42, Article ID: 112508.
https://doi.org/10.1016/j.celrep.2023.112508
|
[26]
|
Bhattacharjee, R., Das, S.S., Biswal, S.S., et al. (2022) Mecha-nistic Role of HPV-Associated Early Proteins in Cervical Cancer: Molecular Pathways and Targeted Therapeutic Strate-gies. Critical Reviews in Oncology/Hematology, 174, Article ID: 103675. https://doi.org/10.1016/j.critrevonc.2022.103675
|
[27]
|
Gupta, B., Kumar, A. and Sridevi, P. (2021) A Comprehen-sive in Silico Analysis for Identification of Immunotherapeutic Epitopes of HPV-18. International Journal of Peptide Research and Therapeutics, 27, 2717-2726.
https://doi.org/10.1007/s10989-021-10285-x
|
[28]
|
Liao, S.J., Deng, D.R., Zeng, D., et al. (2013) HPV16 E5 Pep-tide Vaccine in Treatment of Cervical Cancer in vitro and in vivo. Journal of Huazhong University of Science and Tech-nology, 33, 735-742.
https://doi.org/10.1007/s11596-013-1189-5
|
[29]
|
Liu, D.W., Tsao, Y.P., Hsieh, C.H., et al. (2000) Induction of CD8 T Cells by Vaccination with Recombinant Adenovirus Expressing Human Papillomavirus Type 16 E5 Gene Re-duces Tumor Growth. Journal of Virology, 74, 9083-9089.
https://doi.org/10.1128/JVI.74.19.9083-9089.2000
|
[30]
|
Chen, Y.F., Lin, C.W., Tsao, Y.P. and Chen, S.L. (2004) Cytotoxic-T-Lymphocyte Human Papillomavirus Type 16 E5 Peptide with CpG-Oligodeoxynucleotide Can Eliminate Tumor Growth in C57BL/6 Mice. Journal of Virology, 78, 1333-1343. https://doi.org/10.1128/JVI.78.3.1333-1343.2004
|
[31]
|
张静, 李青峰, 汪琪, 朱珊丽, 陈韶, 张丽芳. HPV16 E5多表位肽免疫原性研究[J]. 免疫学杂志, 2023, 39(4): 341-347.
|
[32]
|
唐婉林, 王路得, 顾美萍, Kamara Saidu, 汪琪, 李明洋, 陈韶, 张丽芳. HPV16 E5蛋白免疫优势肽段分析及其多克隆抗体的制备[J]. 中国生物制品学杂志, 2021, 34(6): 725-729, 739.
|
[33]
|
Qiao, X.W., Jiang, J., Pang, X., et al. (2020) The Evolving Landscape of PD-1/PD-L1 Path-way in Head and Neck Cancer. Frontiers in Immunology, 11, Article 1721. https://doi.org/10.3389/fimmu.2020.01721
|
[34]
|
Mezache, L., Paniccia, B., Nyinawabera, A. and Nuovo, G.J. (2015) Enhanced Expression of PD L1 in Cervical Intraepithelial Neoplasia and Cervical Cancers. Modern Pathology, 28, 1594-1602.
https://doi.org/10.1038/modpathol.2015.108
|
[35]
|
Miyauchi, S., Sanders, P.D., Guram, K., et al. (2020) HPV16 E5 Mediates Resistance to PD-L1 Blockade and Can Be Targeted with Rimantadine in Head and Neck Cancer. Cancer Re-search, 80, 732-746.
https://doi.org/10.1158/0008-5472.CAN-19-1771
|
[36]
|
Wetherill, L.F., Holmes, K.K., Verow, M., et al. (2012) High-Risk Human Papillomavirus E5 Oncoprotein Displays Channel-Forming Activity Sensitive to Small Molecule In-hibitors. Journal of Virology, 86, 5341-5351.
https://doi.org/10.1128/JVI.06243-11
|
[37]
|
Wetherill, L.F., Wasson, C.W., Gemma, S., et al. (2018) Alkyl-Imino Sugars Inhibit the Pro-Oncogenic Ion Channel Function of Human Papillomavirus (HPV) E5. Antiviral Research, 158, 113-121.
https://doi.org/10.1016/j.antiviral.2018.08.005
|